A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
暂无分享,去创建一个
Gerd Geisslinger | Ewgenij Proschak | Daniel Merk | Dieter Steinhilber | Sandra K. Wittmann | D. Steinhilber | M. Wurglics | E. Proschak | D. Merk | G. Geisslinger | A. Paulke | A. Kahnt | J. Heering | Jurema Schmidt | Marco Rotter | Tim Weiser | Lilia Weizel | Astrid Kaiser | Jan Heering | Tamara Goebel | Carlo Angioni | Mario Wurglics | Alexander Paulke | Astrid S. Kahnt | C. Angioni | Jurema Schmidt | L. Weizel | T. Goebel | Astrid Kaiser | T. Weiser | Marco J. Rotter
[1] Manfred Schubert-Zsilavecz,et al. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. , 2012, Future medicinal chemistry.
[2] K. Tomer,et al. The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease , 2014, PloS one.
[3] M. Wang,et al. EETs/sEH in diabetes and obesity-induced cardiovascular diseases. , 2016, Prostaglandins & other lipid mediators.
[4] M. Schubert-Zsilavecz,et al. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present) , 2012, Expert opinion on therapeutic patents.
[5] Richard Morphy,et al. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .
[6] P. Dawson,et al. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives , 2016, Hepatology.
[7] B. Hammock,et al. Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice , 2017, Shock.
[8] G. Schneider,et al. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. , 2014, Journal of medicinal chemistry.
[9] B. Hammock,et al. Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. , 2012, Journal of medicinal chemistry.
[10] Paul D. Jones,et al. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. , 2005, Analytical biochemistry.
[11] J. Boyer,et al. Bile salt transporters: molecular characterization, function, and regulation. , 2003, Physiological reviews.
[12] J. Boyer,et al. Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations. , 2014, Molecular aspects of medicine.
[13] H. Bonkovsky,et al. Recent insights into the biological functions of liver fatty acid binding protein 1 , 2015, Journal of Lipid Research.
[14] K. Tomer,et al. The Cytochrome P 450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease , 2014 .
[15] Ewgenij Proschak,et al. Nonacidic Farnesoid X Receptor Modulators. , 2017, Journal of medicinal chemistry.
[16] Mary E Rinella,et al. Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.
[17] C. Wheelock,et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. , 2002, Biochemical pharmacology.
[18] Om Silakari,et al. Multifunctional compounds: smart molecules for multifactorial diseases. , 2014, European journal of medicinal chemistry.
[19] Janosch Achenbach,et al. Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. , 2012, Biochemical pharmacology.
[20] R. Savkur,et al. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. , 2005, Biochemical and biophysical research communications.
[21] A. Moschetta,et al. Tissue-specific actions of FXR in metabolism and cancer. , 2015, Biochimica et biophysica acta.
[22] G. Costantino,et al. Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding. , 2005, Journal of medicinal chemistry.
[23] S. Fiorucci,et al. Farnesoid X receptor: from structure to potential clinical applications. , 2005, Journal of medicinal chemistry.
[24] G. Schneider,et al. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties. , 2015, Bioorganic & medicinal chemistry.
[25] J. Lehmann,et al. Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.
[26] Philippe Lehert,et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.
[27] Sandra K. Wittmann,et al. N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators. , 2016, Journal of medicinal chemistry.
[28] B. Neuschwander‐Tetri,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.
[29] B. Hammock,et al. Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet–Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice , 2012, PloS one.
[30] M. Makishima,et al. Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.
[31] L. Moore,et al. Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.
[32] Yuan Zhang,et al. Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. , 2013, International journal of cardiology.
[33] N. Chalasani,et al. Pharmacotherapy for Nonalcoholic Fatty Liver Disease , 2015, Seminars in Liver Disease.
[34] M. Schubert-Zsilavecz,et al. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound. , 2016, Future medicinal chemistry.
[35] A. Sanyal. Novel therapeutic targets for steatohepatitis. , 2015, Clinics and research in hepatology and gastroenterology.
[36] K. Lindor,et al. Recent advances in the development of farnesoid X receptor agonists. , 2015, Annals of translational medicine.
[37] S. Mudaliar,et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. , 2013, Gastroenterology.
[38] D. Steinhilber,et al. NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor , 2015, Scientific Reports.
[39] M. Schubert-Zsilavecz,et al. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. , 2006, Planta medica.
[40] K. Cusi,et al. Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[41] G. Bedogni,et al. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease , 2013, PloS one.
[42] L. Adorini,et al. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. , 2012, Drug discovery today.
[43] G. Schneider,et al. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR). , 2014, Bioorganic & medicinal chemistry.
[44] M. Makishima,et al. Identification of a nuclear receptor for bile acids. , 1999, Science.
[45] D. Steinhilber,et al. Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene. , 2007, Biochimica et biophysica acta.
[46] Jasmine Chen,et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.
[47] Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase , 2016, Journal of biomolecular screening.
[48] Bruce D Hammock,et al. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. , 2004, Biochemistry.
[49] J. Peters. Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.
[50] B. Hammock,et al. Soluble epoxide hydrolase: gene structure, expression and deletion. , 2013, Gene.
[51] M. Schubert-Zsilavecz,et al. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands. , 2015, Bioorganic & medicinal chemistry.
[52] John D Imig,et al. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. , 2012, Physiological reviews.
[53] Tian Liu,et al. Soluble Epoxide Hydrolase Inhibitor Suppresses the Expression of Triggering Receptor Expressed on Myeloid Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage , 2016, Inflammation.
[54] K. Tomer,et al. Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity , 2014, Journal of Lipid Research.
[55] G. Poropat,et al. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options , 2015, Drug design, development and therapy.
[56] Richard Morphy,et al. Designing multiple ligands - medicinal chemistry strategies and challenges. , 2009, Current pharmaceutical design.